Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome.
Utilization of hepatitis C seropositive kidney donors remains controversial. We examined the use of hepatitis C seropositive donors for renal transplantation. Data for creatinine, liver function tests, cold ischemia time, and graft and patient survival were analyzed from 20 hepatitis C seropositive recipients receiving cadaveric renal allografts from seropositive donors and were compared with 20 hepatitis C seropositive recipients receiving allografts from seronegative donors. Recipients receiving a kidney from a hepatitis C seropositive donor were on the waitlist for 9.9 +/- 1.8 months, compared with 17.8 +/- 3.3 months for those receiving a kidney from a seronegative donor (p < 0.05). There were no significant differences in graft or patient survival. Incidences of acute cellular rejection and acute tubular necrosis were similar. There were no significant differences in creatinine, alanine aminotransferase, alkaline phosphatase, or bilirubin values. While there was a significant difference in aspartate aminotransferase at 2 wk and 6 months, these differences were of questionable clinical importance. In conclusion, donor seropositivity for hepatitis C should not preclude renal transplantation into a hepatitis C seropositive recipient and utilization of these organs decreases waitlist time for hepatitis C seropositive recipients.
Woodside
Kenneth J
KJ
Department of Surgery, The University of Texas Medical Branch, Galveston, TX, USA.
Ishihara
Kanae
K
Theisen
James E
JE
Early
Marilyn G
MG
Covert
Lesa G
LG
Hunter
Glenn C
GC
Gugliuzza
Kristene K
KK
Daller
John A
JA
D000328:Adult; D005260:Female; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors; D016896:Treatment Outcome; D014850:Waiting Lists
D018937:Hepatitis C Antibodies